Skip to main content

Table 3 Small-molecule compounds targeting Wnt/β-catenin cascade to inhibit cancer stem cells

From: Targeting the Wnt/β-catenin signaling pathway in cancer

Agents Target Phase Type of cancer Side effects References
WNT974 PORCN inhibitor Phase I Breast cancer Not reported Solzak JP et al. [136]
Niclosamide Wnt/β-catenin Phase II Colorectal cancer Vomiting, diarrhea, and colitis Burock S et al. [140]
  Wnt/β-catenin Preclinical Ovarian cancer Not reported Lin CK et al. [137]
  LRP6, β-catenin Preclinical Basal-like breast cancer Not reported Ye T et al. [139]
ONC201 Wnt/β-catenin Phase I/ II Glioblastoma cancer Not reported Arrillaga-Romany I et al. [144]
   Preclinical Prostate cancer Not reported Lev A et al. [143]
XAV939 Tankyrase inhibitor Preclinical Colon cancer Not reported Wu X et al. [147]
   Preclinical Head and neck squamous cell carcinoma Not reported Roy S et al. [146]
IWR-1 Tankyrase inhibitor Preclinical Osteosarcoma Not reported Martins-Neves SR et al. [148]
TFP Wnt/β-catenin Preclinical Lung cancer Not reported Yeh CT et al. [118]
AD and Ts Wnt/β-catenin Preclinical Lung cancer Not reported Lamture G et al. [165]
Chelerythrine β-catenin Preclinical Non-small cell lung carcinoma Not reported Medvetz D et al. [150]
Wnt-C59 PORCN inhibitor Preclinical Nasopharyngeal carcinoma Not reported Cheng Y et al. [152]
IC-2 Wnt Preclinical Hepatocellular carcinoma Not reported Seto K et al
   Preclinical Colorectal cancer Not reported Urushibara S et al
JIB-04 β-catenin Preclinical Colorectal cancer Not reported Kim M et al. [153]
FH535 Wnt/β-catenin Preclinical Pancreatic cancer Not reported Razak S et al. [155]
Docetaxel and sulforaphane β-catenin Preclinical Breast cancer Not reported de Bessa Garcia SA et al. [157]
Pyrvinium pamoate β-catenin Preclinical Breast cancer Not reported Xu L et al. [158]
SKL2001 Axin/β-catenin Preclinical Mesenchymal stem cell Not reported Jiwon Choi et al. [159]